ATRA
ATRA clinical trials: Atara Biotherapeutics, Inc.
Every trial on ClinicalTrials.gov where Atara Biotherapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 8
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ATRA on the catalyst calendar · ATRA registry changes
- Primary completion Mar 3, 2025ActualPhase 1NCT06256484A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaAtara Biotherapeutics · Relapsed/Refractory B-cell Non-Hodgkin LymphomaTerminatedATRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 16, 2025ActualPhase 1NCT06429800A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus ErythematosusAtara Biotherapeutics · Lupus NephritisWithdrawnATRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2021ActualPhase 1/Phase 2NCT03769467Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Atara Biotherapeutics · Nasopharyngeal CarcinomaTerminatedATRALeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 9, 2023ActualPhase 1/Phase 2NCT03283826Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisAtara Biotherapeutics · Primary Progressive Multiple SclerosisTerminatedATRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT02822495Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or MalignanciesAtara Biotherapeutics · Epstein-Barr Virus (EBV) InfectionsNo longer availableATRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2019ActualPhase 1/Phase 2NCT00002663Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesAtara Biotherapeutics · EBV-induced LymphomasCompletedATRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2019ActualPhase 2NCT01498484Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party...Atara Biotherapeutics · EBV-induced LymphomasCompletedATRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03010332Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or DiseaseAtara Biotherapeutics · CMV ViremiaNo longer availableATRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 1NCT04577326Mesothelin-targeted CAR T-cell Therapy in Patients With MesotheliomaMemorial Sloan Kettering Cancer Center · Malignant Pleural Mesothelioma (MPM)Active, not recruitingATRACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2021ActualPhase 1NCT00620633Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell...Memorial Sloan Kettering Cancer Center · LeukemiaCompletedATRACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2019ActualPhase 2NCT01646645Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic...Memorial Sloan Kettering Cancer Center · CytomegalovirusCompletedATRACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner